glp-1 employer coverage news october 2025 Employers across America are dropping weight-loss drug as costs explode, leaving employees to choose between health and finances. Read more below Annual Family Premiums for Employer

the Neurofibromatosis Therapeutic Acceleration Program

SelectHealth has published PA criteria for Wegovy (BMI 30 or higher, or 27 or higher with comorbidity, documented prior weight-loss attempts) a more concrete conditional-covered framework than Regence, whose Wegovy detail is not publicly published

At consultation we will recommend the product that best fits your area, your tolerance for downtime and your schedule

Semaglutide is a GLP-1 agonist currently used to treat type 2 diabetes and for weight management via subcutaneous injection or taken orally

Pancreaticoduodenal arteries compensate for mesenteric occlusion

Approximately a third of patients with frequent PVCs develop cardiomyopathy